NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
Goodbody Health Inc.
(“Goodbody” or “Goodbody Health” the “Company” or the “Group”)
7th February 2022
Goodbody Health Group receives extension of scope of ISO 17025 to meet Government Chemist and ACMD Guidance.
Goodbody Health Inc is pleased to announce its subsidiary Phytovista Laboratories has achieved another significant milestone with an extension to its ISO 17025 UKAS accreditation with a test to meet Government Chemist and the Advisory Council on the Misuse of Drugs (“ACMD”) Guidance, one of a very small number of laboratories accredited for this type of testing.
As identified in the 2021 Government Chemist CBD Food and Cosmetic Ring Trial report, and others, advanced testing methodology is desirable to give the required sensitivity and selectivity to reliably detect traces of residues of controlled cannabinoids in consumer CBD products.
PhytoVista laboratories is now ideally positioned to help CBD companies achieve compliance by providing data in accordance with the ACMD guidance on acceptable levels of controlled cannabinoids in consumer products.
The Government Chemist has been recognised for their contribution in advising government and contributing to the ACMD, enabling the UK to lead the way in creating a fully regulated Novel Food consumer CBD market, facilitating consumer choice and confidence.
Geremy Thomas, Executive Chairman, said; “This is another example to show how we as a group not only lead the way in supplying the best quality products but also continue to support the whole CBD industry to put quality and compliance first.”
For further information:
Chief Executive Officer
Goodbody Health Inc.
+44 (0) 20 7971 1255
AQSE Growth Market Corporate Advisor
Antonio Bossi / George Morgan
Arden Partners Ltd
+ 44 (0) 20 7614 5900